178 related articles for article (PubMed ID: 11149559)
1. Glomerular and tubular renal functions after long-term medication of sulphasalazine, olsalazine, and mesalazine in patients with ulcerative colitis.
Birketvedt GS; Berg KJ; Fausa O; Florholmen J
Inflamm Bowel Dis; 2000 Nov; 6(4):275-9. PubMed ID: 11149559
[TBL] [Abstract][Full Text] [Related]
2. 5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine.
Stretch GL; Campbell BJ; Dwarakanath AD; Yaqoob M; Stevenson A; Morris AI; Rhodes JM
Aliment Pharmacol Ther; 1996 Dec; 10(6):941-7. PubMed ID: 8971292
[TBL] [Abstract][Full Text] [Related]
3. Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease.
Mahmud N; Weir DG; Kelleher D
Ir J Med Sci; 1999; 168(4):228-32. PubMed ID: 10624358
[TBL] [Abstract][Full Text] [Related]
4. The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine.
Støa-Birketvedt G; Florholmen J
Aliment Pharmacol Ther; 1999 Mar; 13(3):357-61. PubMed ID: 10102969
[TBL] [Abstract][Full Text] [Related]
5. Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine.
Rao SS; Cann PA; Holdsworth CD
Scand J Gastroenterol; 1987 Apr; 22(3):332-6. PubMed ID: 2884724
[TBL] [Abstract][Full Text] [Related]
6. Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine.
Karamanolis DG; Papatheodoridis GV; Xourgias V
Eur J Gastroenterol Hepatol; 1996 Nov; 8(11):1083-8. PubMed ID: 8944370
[TBL] [Abstract][Full Text] [Related]
7. Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission.
Ewe K; Becker K; Ueberschaer B
Z Gastroenterol; 1996 Apr; 34(4):225-9. PubMed ID: 8686349
[TBL] [Abstract][Full Text] [Related]
8. Tests of renal function in patients with quiescent colitis: effects of drug treatment.
Riley SA; Lloyd DR; Mani V
Gut; 1992 Oct; 33(10):1348-52. PubMed ID: 1446858
[TBL] [Abstract][Full Text] [Related]
9. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
Rachmilewitz D
BMJ; 1989 Jan; 298(6666):82-6. PubMed ID: 2563951
[TBL] [Abstract][Full Text] [Related]
10. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse.
Riley SA; Mani V; Goodman MJ; Herd ME; Dutt S; Turnberg LA
Gut; 1988 May; 29(5):669-74. PubMed ID: 2899536
[TBL] [Abstract][Full Text] [Related]
11. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis.
Courtney MG; Nunes DP; Bergin CF; O'Driscoll M; Trimble V; Keeling PW; Weir DG
Lancet; 1992 May; 339(8804):1279-81. PubMed ID: 1349676
[TBL] [Abstract][Full Text] [Related]
12. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis.
Kruis W; Brandes JW; Schreiber S; Theuer D; Krakamp B; Schütz E; Otto P; Lorenz-Mayer H; Ewe K; Judmaier G
Aliment Pharmacol Ther; 1998 Aug; 12(8):707-15. PubMed ID: 9726382
[TBL] [Abstract][Full Text] [Related]
13. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study.
Nilsson A; Danielsson A; Löfberg R; Benno P; Bergman L; Fausa O; Florholmen J; Karvonen AL; Kildebo S; Kollberg B
Am J Gastroenterol; 1995 Mar; 90(3):381-7. PubMed ID: 7872274
[TBL] [Abstract][Full Text] [Related]
14. Treatment of ulcerative colitis with olsalazine and sulphasalazine: efficacy and side-effects.
Ewe K; Eckardt V; Kanzler G
Scand J Gastroenterol Suppl; 1988; 148():70-5. PubMed ID: 2906479
[TBL] [Abstract][Full Text] [Related]
15. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis.
Kruis W; Judmaier G; Kayasseh L; Stolte M; Theuer D; Scheurlen C; Hentschel E; Kratochvil P
Eur J Gastroenterol Hepatol; 1995 May; 7(5):391-6. PubMed ID: 7614099
[TBL] [Abstract][Full Text] [Related]
16. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine.
Giaffer MH; O'Brien CJ; Holdsworth CD
Aliment Pharmacol Ther; 1992 Feb; 6(1):51-9. PubMed ID: 1347468
[TBL] [Abstract][Full Text] [Related]
17. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion.
Staerk Laursen L; Stokholm M; Bukhave K; Rask-Madsen J; Lauritsen K
Gut; 1990 Nov; 31(11):1271-6. PubMed ID: 2253912
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis.
Mahmud N; O'Toole D; O'Hare N; Freyne PJ; Weir DG; Kelleher D
Aliment Pharmacol Ther; 2002 Feb; 16(2):207-15. PubMed ID: 11860403
[TBL] [Abstract][Full Text] [Related]
19. Controlled trial comparing olsalazine and sulphasalazine for maintenance treatment of ulcerative colitis.
Jewell DP; Ireland A
Scand J Gastroenterol Suppl; 1988; 148():45-7. PubMed ID: 2906477
[TBL] [Abstract][Full Text] [Related]
20. Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study.
Rao SS; Dundas SA; Holdsworth CD; Cann PA; Palmer KR; Corbett CL
Gut; 1989 May; 30(5):675-9. PubMed ID: 2567266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
